Xlife Sciences AG Ordinary Shares XLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CHF 36.60
- Day Range
- CHF 34.50–36.10
- 52-Week Range
- CHF 31.50–51.40
- Bid/Ask
- CHF 34.50 / CHF 37.50
- Market Cap
- CHF 201.90 Mil
- Volume/Avg
- 27,093 / 9,697
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 259.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial intelligence/digital medicine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 17
- Website
- https://www.xlifesciences.ch
Comparables
Valuation
|
Metric
|
XLS
|
INA
|
KOMN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 21.96 | 21.17 |
Price/Book Value | 0.74 | 0.80 | 2.22 |
Price/Sales | 259.43 | 11.82 | 1.15 |
Price/Cash Flow | 53.51 | — | 15.04 |
Price/Earnings
XLS
INA
KOMN
Financial Strength
|
Metric
|
XLS
|
INA
|
KOMN
|
|---|---|---|---|
Quick Ratio | 3.11 | 0.05 | 1.71 |
Current Ratio | 3.11 | 0.16 | 3.11 |
Interest Coverage | 12.70 | −1.35 | 12.75 |
Quick Ratio
XLS
INA
KOMN
Profitability
|
Metric
|
XLS
|
INA
|
KOMN
|
|---|---|---|---|
Return on Assets (Normalized) | −7.80% | −1.30% | 5.48% |
Return on Equity (Normalized) | −15.67% | −4.95% | 10.15% |
Return on Invested Capital (Normalized) | −9.47% | −0.85% | 7.66% |
Return on Assets
XLS
INA
KOMN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vqgtgwdcm | Vyt | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lxzhtfz | Cvpfw | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qpcmmnv | Qcphkyc | $107.6 Bil | |
MRNA
| Moderna Inc | Xhrqwllq | Wpn | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Whvgqxbg | Lqwv | $22.2 Bil | |
ARGX
| argenx SE ADR | Wkkktvnm | Hhp | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gwlfhkc | Dfcmkhp | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vnlfvvqx | Lpcmgkq | $15.1 Bil | |
INCY
| Incyte Corp | Sfrkpbpp | Nhxlx | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zbwrnypyk | Dlcln | $12.7 Bil |